1. Li, Z., Yin, S., Sun, M., Cheng, X., Wei, J., Gilbert, N., Miao, J., Cui, L., Huang, Z., Dai, X., & Jiang, L. (2019). DNA helicase RecQ1 regulates mutually exclusive expression of virulence genes in Plasmodium falciparum via heterochromatin alteration. Proceedings of the National Academy of Sciences of the United States of America, 116(8), 3177–3182. （共同通讯）

2. Huang, Z., Li, R., Tang, T., Ling, D., Wang, M., Xu, D., Sun, M., Zheng, L., Zhu, F., Min, H., Boonhok, R., Ding, Y., Wen, Y., Chen, Y., Li, X., Chen, Y., Liu, T., Han, J., Miao, J., Fang, Q., … Jiang, L. (2020). A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1. Cell discovery, 6(1), 93. （一作/共同通讯）

3. Chen, W., Huang, Z., Wang, W., Mao, F., Guan, L., Tang, Y., Jiang, H., Li, J., Huang, J., Jiang, L., & Zhu, J. (2017). Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely. Bioorganic & medicinal chemistry, 25(24), 6467–6478. (共同一作)

4. Liang, X., Jiang, Z., Huang, Z., Li, F., Chen, C., Hu, C., Wang, W., Hu, Z., Liu, Q., Wang, B., Wang, L., Qi, Z., Liu, J., Jiang, L., & Liu, Q. (2020). Discovery of 6'-chloro-N-methyl-5'-(phenylsulfonamido)-[3,3'-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium. European journal of medicinal chemistry, 188, 112012. （共同一作）

5. Chen, W., X. Yao, Z. Huang, F. Mao, L. Guan, Y. Tang, H. Jiang, J. Li, J. Huang, L. Jiang and J. Zhu (2019). "Novel dual inhibitors against FP-2 and PfDHFR as potential antimalarial agents: Design, synthesis and biological evaluation." Chinese Chemical Letters 30(1): 250-254.（共同一作）

6. Xiao, B., Yin, S., Hu, Y., Sun, M., Wei, J., Huang, Z., Wen, Y., Dai, X., Chen, H., Mu, J., Cui, L., & Jiang, L. (2019). Epigenetic editing by CRISPR/dCas9 in Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America, 116(1), 255–260.

7. Zhou, J., Huang, Z., Zheng, L., Hei, Z., Wang, Z., Yu, B., Jiang, L., Wang, J., & Fang, P. (2020). Inhibition of Plasmodium falciparum Lysyl-tRNA synthetase via an anaplastic lymphoma kinase inhibitor. Nucleic acids research, 48(20), 11566–11576.

8. Li, R., Ling, D., Tang, T., Huang, Z., Wang, M., Ding, Y., Liu, T., Wei, H., Xu, W., Mao, F., Zhu, J., Li, X., Jiang, L., & Li, J. (2021). Discovery of Novel Plasmodium falciparum HDAC1 Inhibitors with Dual-Stage Antimalarial Potency and Improved Safety Based on the Clinical Anticancer Drug Candidate Quisinostat. Journal of medicinal chemistry, 64(4), 2254–2271.

9. Wang, M., Tang, T., Li, R., Huang, Z., Ling, D., Zheng, L., Ding, Y., Liu, T., Xu, W., Zhu, F., Min, H., Boonhok, R., Mao, F., Zhu, J., Li, X., Jiang, L., & Li, J. (2022). Drug Repurposing of Quisinostat to Discover Novel Plasmodium falciparum HDAC1 Inhibitors with Enhanced Triple-Stage Antimalarial Activity and Improved Safety. Journal of medicinal chemistry, 65(5), 4156–4181.

10. Yang, Y., Yu, Y., Li, X., Li, J., Wu, Y., Yu, J., Ge, J., Huang, Z., Jiang, L., Rao, Y., & Yang, M. (2017). Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria. Journal of medicinal chemistry, 60(5), 1994–2005.

11. Li, R., D. Ling, T. Tang, Z. Huang, M. Wang, F. Mao, J. Zhu, L. Jiang, J. Li and X. Li (2020). "Repurposing of antitumor drug candidate Quisinostat lead to novel spirocyclic antimalarial agents." Chinese Chemical Letters.

12. Wang, M., T. Tang, Z. Huang, R. Li, D. Ling, J. Zhu, L. Jiang, J. Li and X. Li (2022). "Design and synthesis of novel hydroxamic acid derivatives based on quisinostat as promising antimalarial agents with improved safety." Acta Materia Medica 1(2).

13. Yang, Y., T. Tang, X. Li, T. Michel, L. Ling, Z. Huang, M. Mulaka, Y. Wu, H. Gao, L. Wang, J. Zhou, B. Meunier, H. Ke, L. Jiang and Y. Rao (2021). "Design, synthesis, and biological evaluation of multiple targeting antimalarials." Acta Pharm Sin B 11(9): 2900-2913.

14. Cheng, Z. L., Zhang, M. L., Lin, H. P., Gao, C., Song, J. B., Zheng, Z., Li, L., Zhang, Y., Shen, X., Zhang, H., Huang, Z., Zhan, W., Zhang, C., Hu, X., Sun, Y. P., Jiang, L., Sun, L., Xu, Y., Yang, C., Ge, Y., … Ye, D. (2020). The Zscan4-Tet2 Transcription Nexus Regulates Metabolic Rewiring and Enhances Proteostasis to Promote Reprogramming. Cell reports, 32(2), 107877.

15. Xu, Y., Qiao, D., Wen, Y., Bi, Y., Chen, Y., Huang, Z., Cui, L., Guo, J., & Cao, Y. (2021). PfAP2-G2 Is Associated to Production and Maturation of Gametocytes in Plasmodium falciparum via Regulating the Expression of PfMDV-1. Frontiers in microbiology, 11, 631444.

16. Gao, H., Bai, L., Jiang, Y., Huang, W., Wang, L., Li, S., Zhu, G., Wang, D., Huang, Z., Li, X., Cao, J., Jiang, L., Jacobs-Lorena, M., Zhan, S., & Wang, S. (2021). A natural symbiotic bacterium drives mosquito refractoriness to Plasmodium infection via secretion of an antimalarial lipase. Nature microbiology, 6(6), 806–817.

专利

1、 Quisinostat，一种新型的高效抗疟药物，江陆斌；黄正辉，申请号：201610096388.9，中国科学院上海巴斯德研究所，申请日期：2016年2月22日。

2、 环状或螺环二胺类嘧啶-异羟肟酸及其用途，李剑；江陆斌；李若曦；黄正辉；汤同柯；凌大正；王熳炯；朱进，专利号：ZL201910212087.1，华东理工大学；中国科学院上海巴斯德研究所，申请日期：2019年3月20日。

3、 2，8-二氮杂-螺-[4,5]-癸烷类嘧啶-异羟肟酸化合物及其用途，李剑；江陆斌；李若曦；汤同柯；黄正辉；凌大正；王熳炯；朱进，专利号：ZL201910214972.3，华东理工大学；中国科学院上海巴斯德研究所，申请日期：2019年3月20日。

4、 2,7-二氮杂-螺[4.4]壬烷类异羟肟酸嘧啶类化合物及其制备和应用，李剑；江陆斌；凌大正；黄正辉；王熳炯；李若曦；汤同柯；朱进，申请号：PCT/CN2019/077357，华东理工大学；中国科学院上海巴斯德研究所，申请日期：2019年3月7日。

　　以原创的表观遗传基因编辑技术为手段，研究疟疾发病过程中介导疟原虫免疫逃逸和多通路感染的表观遗传调控机制，挖掘疟疾疫苗和抗疟药研发的新靶点，探索疟疾防控的新策略。相关研究成果发表在NAS>、< Nucleic acids research >、 Discovery>、等重要国际学术期刊。作为项目负责人先后主持了国家、省部级竞争性科研/人才项目多项，其中中科院特别研究助理项目和上海市“超级博士后”激励计划等项目已顺利完成结题；目前在研国家自然科学基金青年项目1项、中国科学院青促会项目1项和所级青年人才项目1项。

　　依托疟原虫表观遗传学研究组开展科研工作。我们以原创的表观遗传基因编辑技术为手段，研究疟疾感染过程中介导疟原虫免疫逃逸、多通路感染和寄生虫耐药的表观遗传调控机制，重点聚焦疟原虫红内期生长发育的表观遗传调控机制研究，并在此基础上挖掘新型疟疾疫苗和抗疟药研发的新靶点、探索疟疾防控的新策略。